| iTReX: Interactive exploration of mono-and combination therapy dose response profiling data D ElHarouni, Y Berker, H Peterziel, A Gopisetty, L Turunen, S Kreth, ... Pharmacological research 175, 105996, 2022 | 13 | 2022 |
| Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies KM Keller, S Krausert, A Gopisetty, D Luedtke, J Koster, NA Schubert, ... European Journal of Cancer 162, 107-117, 2022 | 11 | 2022 |
| The genomic landscape of pediatric renal cell carcinomas P Beck, B Selle, L Madenach, DTW Jones, C Vokuhl, A Gopisetty, A Nabbi, ... Iscience 25 (4), 2022 | 5 | 2022 |
| ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models E Indersie, S Branchereau, B Fresneau, C Chardot, D Surdez, ... Cancer Research 84 (6_Supplement), 5469-5469, 2024 | | 2024 |
| ITCC-P4: Molecular characterization and multi-omics analysis of pediatric patient tumor and Patient-Derived Xenograft (PDX) models for preclinical model selection A Gopisetty | | 2024 |
| ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing A Gopisetty, A Federico, D Surdez, Y Iddir, S Zaidi, A Saint-Charles, ... Cancer Research 83 (7_Supplement), 234-234, 2023 | | 2023 |
| The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models A Federico, A Gopisetty, D Surdez, Y Iddir, A Saint-Charles, J Wierzbinska, ... Cancer Research 83 (7_Supplement), 3571-3571, 2023 | | 2023 |
| EPCO-47. ITCC-P4: GENOMIC PROFILING AND ANALYSES OF PEDIATRIC PATIENT TUMOR AND PATIENT-DERIVED XENOGRAFT (PDX) MODELS FOR HIGH THROUGHPUT IN VIVO TESTING A Gopisetty, A Federico, D Surdez, E Saberi-Ansari, Y Iddir, ... Neuro-Oncology 24 (Supplement_7), vii126-vii127, 2022 | | 2022 |
| R-LOOPS IN PEDIATRIC BRAIN TUMORS S Wang, A Gopisetty, N Jaeger, S Pfister, M Kool NEURO-ONCOLOGY 24, 183-184, 2022 | | 2022 |
| INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughputin vivo testing M Kool, A Federico, D Surdez, A Gopisetty, E Saberi-Ansari, ... Neuro-Oncology 24 (Supplement_1), i189-i189, 2022 | | 2022 |
